The multinational pharmaceutical company Acino, which has its headquarters in Switzerland, has big plans to expand locally and internationally from its manufacturing plant in Dubai Science Park.
Acino has concentrated on the Middle East and emerging markets. According to Mansoor Meenai, Acino’s interim head of region for the Middle East, Turkey, and Africa, “we have active plans for the GCC markets and beyond.”
Acino, a Swiss company founded in 1836 close to Basel, was purchased by ADQ, an Abu Dhabi holding and investment company, in 2022. The activities of Pharmax, a nearby pharmaceutical manufacturer, merged with Acino last year. “To determine how we can expand this site to achieve greater scale and benefits, we combined local knowledge and investment with the manufacturing expertise of Europe and the world.
Acino’s Dubai plant is an EU-GMP, SFA, and GCC-certified manufacturing site, with stamps of approval that are expected to engender renewed trust in the regional pharmaceutical supply chain. The plant is expected to support industry growth alongside the improvement of service access for patients, enhanced quality of care, and more favorable treatment outcomes.
